Business Context and Reporting Period
This Form 8-K Current Report was filed by Artelo Biosciences, Inc. on March 26, 2026, covering events occurring on March 20, 2026, and March 25, 2026. The Company is a Nevada corporation with its principal executive offices in Solana Beach, California, and its common stock trades on The Nasdaq Stock Market under the symbol ARTL.
Key Financial Metrics and Capital Structure
The filing details a specific financing transaction rather than periodic financial performance metrics such as revenue or operating margins.
- Debt Issuance: The Company issued a 10% promissory note with an aggregate principal amount of $315,000.
- Proceeds: The aggregate purchase price was $300,000, reflecting an original issue discount (OID) of $15,000.
- Transaction Costs: The Company is responsible for $7,500 in due diligence and legal fees for the investor.
- Use of Proceeds: Funds are designated for business development and general working capital.
- Liquidity Impact: The filing does not provide current cash balances or liquidity ratios; it only confirms the intent to raise capital for working capital purposes.
Material Changes and Agreements
The primary material change is the entry into a Securities Purchase Agreement with Labrys Fund II, L.P. Key terms include:
- Maturity: The note matures 12 months from the issue date (March 20, 2027).
- Prepayment: The Company may prepay the note in full after 181 calendar days from the issue date.
- Conversion Rights: The investor may convert the principal and accrued interest into common stock on or after 180 days from the issue date, or upon registration of resale rights.
- Conversion Price: Set at 75% of the average of the two lowest closing bid prices during the 10 trading days prior to conversion.
- Ownership Cap: Conversion is limited to prevent the investor from beneficially owning more than 4.99% of outstanding shares (adjustable up to 9.99% with notice).
- Default Provisions: Upon an Event of Default, the outstanding amount becomes immediately due and payable at 150% of the principal plus accrued interest and collection costs.
Outlook, Risks, and Unusual Items
Strategic Update: On March 25, 2026, the Company issued a press release regarding a strategic expansion opportunity for its asset ART27.13, focusing on muscle preservation for patients undergoing glucagon-like peptide-1 receptor agonist therapy.
Risks and Contingencies:
- Dilution Risk: The conversion feature allows the investor to acquire shares at a significant discount (75% of the lowest recent prices), which could materially dilute existing shareholders if triggered.
- Default Penalty: The 150% penalty multiplier upon default represents a significant financial contingency.
- Forward-Looking Statements: The press release contains forward-looking statements regarding ART27.13 that involve substantial risks and uncertainties; actual results may differ materially from expectations.
Investor Verification Checklist
- Verify the current trading price of ARTL to assess the potential dilution impact of the 75% conversion discount.
- Review the Company's latest 10-Q or 10-K to determine if the $300,000 proceeds are sufficient to meet near-term working capital needs.
- Confirm the specific clinical data or regulatory status supporting the ART27.13 muscle preservation announcement in the attached press release (Exhibit 99.1).
- Monitor for any future filings regarding the registration of the conversion shares, which would trigger the investor's right to convert.